glp 1 analog mechanism of action GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs)

This triple agonism distinguishes retatrutide from existing approved agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 agonist)

Higher-tier drugs, which often include newer or more expensive medications like GLP-1 receptor agonists, usually have higher copays or coinsurance

For many individuals, digestive symptoms are most noticeable: during the first few weeks, after dose increases, or after eating large high-fat meals

The adverse effects of GLP-1RA, such as nausea, constipation, and diarrhea, are thought to be the result of the pharmacological action of GLP-1, but the mechanisms have not been fully elucidated